Evidence map›Paper›PMID 28050125›Full record

ArticleMolecular vision2016

Somatostatin protects photoreceptor cells against high glucose-induced apoptosis.

Ana I Arroba, Aurora Mazzeo, Daniele Cazzoni, Elena Beltramo, Cristina Hernández, Massimo Porta, Rafael Simó, Ángela M Valverde

Open access · greenAbstract read
In one paragraph

Article in Molecular vision, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 32 citations in OpenAlex.

  1. Neuroprotection in Early Diabetic Retinal Disease Using Eyedrop Delivery.International journal of molecular sciences · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. PACAP for Retinal Health: Model for Cellular Aging and Rescue.International journal of molecular sciences · 2021
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Neuroprotective Peptides in Retinal Disease.Journal of clinical medicine · 2019
    Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ana I ArrobaAlberto Sols Biomedical Research Institute (IIBm) (CSIC/UAM), 28029 Madrid, Spain; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERdem), ISCIII, Madrid, Spain.
Aurora Mazzeo
Daniele CazzoniAlberto Sols Biomedical Research Institute (IIBm) (CSIC/UAM), 28029 Madrid, Spain.
Elena Beltramo
Cristina HernándezSpanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERdem), ISCIII, Madrid, Spain.
Massimo Porta
Rafael SimóSpanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERdem), ISCIII, Madrid, Spain.
Ángela M ValverdeAlberto Sols Biomedical Research Institute (IIBm) (CSIC/UAM), 28029 Madrid, Spain; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERdem), ISCIII, Madrid, Spain.
Instituto de Investigaciones Biomédicas Sols-Morreale · ESInstituto de Salud Carlos III · ESSpanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMany cellular and molecular studies in experimental animals and early retinal function tests in patients with diabetic retinopathy (DR) have shown that retinal neurodegeneration is an early event in the pathogenesis of the disease. Somatostatin (SST) is one of the most important neuroprotective factors synthesized by the retina: SST levels are decreased in parallel to retinal neurodegeneration in early stages of DR. In this study, we characterized the induction of apoptosis (programmed cell death) in a 661W photoreceptor-like cell line cultured under high glucose (HG) conditions and the effect of SST.

methodsA 661W photoreceptor-like cell line and retinal explants from 10-week-old male C57BL/6 mice were cultured under HG conditions and treated with SST.

resultsHyperglycemia significantly reduced the cellular viability by increasing the percentage of apoptotic cells, and this effect was ameliorated by SST (p˂0.05). Activation of caspase-8 by hyperglycemia was found in the 661W cells and retinal explants and decreased in the presence of SST (p˂0.05). Moreover, we detected activation of calpain-2 associated with hyperglycemia-induced cell death, as well as increased protein tyrosine phosphatase 1B (PTP1B) protein levels; both had a pattern of cleavage that was absent in the presence of SST (p˂0.05). Treatment of the 661W cells and retinal explants with SST for 24 h increased the phosphorylation of type 1 insulin-like growth factor receptor (IGF-IR; tyrosine 1165/1166) and protein kinase B (Akt; serine 473), suggesting this survival signaling is activated in the neuroretina by SST (p˂0.05).

conclusionsThis study has provided new mechanistic insights first into the involvement of calpain-2 and PTP1B in the loss of cell survival and increased caspase-8-dependent apoptosis induced by hyperglycemia in photoreceptor cells and second, on the protective effect of SST against apoptosis by the enhancement of IGF-IR-mediated Akt phosphorylation.

Indexed as

AnimalsApoptosisCalpainCaspase 8Cell LineCell SurvivalCytoprotectionEnzyme ActivationGlucoseHyperglycemiaMaleMice, Inbred C57BLPhosphorylationPhotoreceptor CellsProtein Tyrosine Phosphatase, Non-Receptor Type 1Proto-Oncogene Proteins c-aktCalpainCaspase 8GlucoseProtein Tyrosine Phosphatase, Non-Receptor Type 1Proto-Oncogene Proteins c-aktReceptor, IGF Type 1Somatostatin

Identifiers

PMID28050125
PMCPMC5204461
OpenAlexW2570254775

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.